Shiitake mushrooms mycelia extract

  • Enhances antibody production
  • Supports a healthy immune system
  • Clinically studied and developed in Japan
Gluten Free

$131.19 or subscribe and save 20%

Out of stock

AHCC® is a natural compound extracted from shiitake mushrooms. It was developed in Japan in 1989, and has since been used to improve the immunity of over 100,000 patients, and has been studied in over 50 human clinical trials. AHCC® has the unique ability to stimulate the immune system, which is important in controlling inflammation and infection and regulating healthy cell growth.

AHCC® is used alongside chemotherapy treatments in many Japanese hospitals for its immune supportive effects. The majority of studies have shown reduced side effects, increased quality of life and improved survival rates. Patients taking AHCC® reported less nausea, vomiting and hair loss, and AHCC® improved their body weight and appetite during chemotherapy. The immune effects of AHCC® are not limited to cancer patients and have been applied to microbial infections as well. AOR’s AHCC® is a powerful, evidence based option for people that want to support their immune function, combat stubborn infections and for patients undergoing certain types of chemotherapy.


AHCC® is a unique antioxidant and immune system modulator. AOR’s AHCC® contains one of the highest doses found on the market with the fewest additional ingredients. The active ingredients of AHCC® include acetylated alpha-glucan for optimal bioavailability.




AHCC® is an extracted compound derived from shiitake mushrooms, and provides powerful antioxidant support. The active ingredients of AHCC® include acetylated alpha for optimal bioavailability.


AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Adult Dosage

Take 2 capsules daily, preferably without food, or as directed by a qualified health care practitioner.


Do not take if you are pregnant or breastfeeding or if you are allergic to corn. Nausea and diarrhea have been known to occur, in which case, discontinue use.

Main Applications
  • Immune system support
  • Healthy inflammatory response
  • Normal cell production and differentiation

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: 2 Capsule

AHCC® is a registered trademark of Amino Up Co. LTD and is a standardized extract of cultured Lentinula.

Non-medicinal ingredients: alpha-cyclodextrin, dextrin, microcrystalline cellulose, carnauba wax.

Capsule : hypromellose.

Immunity Support:
Study 1:
The aim of this placebo-controlled, randomized study was to assess the effects of AHCC supplementation on immune responses in healthy volunteers. 21 participants were randomized to receive either a placebo or AHCC at 3 g per day for four weeks and monitored for the number and function of circulating dendritic cells (DC), natural killer (NK) cells and the proliferative response of T lymphocytes towards mitogen phytohemagglutinin (PHA). Cytokine production stimulated by lipopolysaccharide [interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, tumor necrosis factor-alpha) were measured as well.

In the AHCC group, researchers found significant increases in the total numbers of total DCs compared to the baseline and placebo groups. Allogeneic mixed-leukocyte reaction (MLR) in the AHCC supplemented group was also significantly increased. These results suggest the role of AHCC in specific immunity.

Study 2:
AHCC is believed to be an immune enhancer, especially in situations where the immune system is compromised. The objective of this study was to evaluate the effects of this compound on the immune function of healthy adults aged 50 years or older. Following AHCC supplementation, peripheral blood was obtained from subjects and assessed for the production of interferon (IFN)-γ, tumor necrosis factor (TNF)-α by CD4(+) and CD8(+) T cells. The frequency of CD4(+) and CD8(+) T cells producing IFN-γ alone, TNF-α alone, or both increased during AHCC intake compared with baseline values. It was important to note that 30 days following cessation of AHCC supplementation, subject still had enhanced CD4(+) and CD8(+) T cell immune responses, confirming the immune-enhancing effects of AHCC in healthy subjects.

Study 3:
This study was a 4-week, randomized, double-blind, parallel-group, placebo-controlled, with the specific aim of evaluating the effects of AHCC intake on immune competence in healthy individuals. Participants received either a placebo or AHCC (1g/day) for four weeks in early winter and were monitored for immune activity, through natural killer (NK) cell activity, scores of immunological vigor, an index of total immune competence.

The results show a significant increase in NK cell activity, while the placebo group showed a remarkable decline in NK cell activity. additionally, the score of immunological vigor was maintained in the AHCC group, compared to a decrease in scores in the placebo group, suggesting that AHCC supplementation helped healthy individuals maintain immune competence against seasonal changes.

Study 4:
T helper (Th) cells are a critical part of the immune response. Interleukin-1β (IL-1β) is produced by immune monocytes that can affect the development of Th17 and Th1 cells, which are responsible for the production of IL-17 and interferon (IFN)-γ respectively. This was not a clinical study, but an in-vitro (cell culture) study to determine if the polysaccharides in AHCC was able to modulate immune responses through its effects on interleukins and T helper cells.

The results from this study show that AHCC induced high levels of IL-1β, as well as increased the production of IL-17 and IFN-γ from CD4(+) cells, suggesting that AHCC could enhance immunity by modulating monocytes and T helper cells.

Study 5:
The idea that supplementation with specific natural health products can help stimulate the human immune response to vaccination has been discussed for years. Mice studies have been used to show that AHCC supplementation in mice protected them from lethal primary influenza, especially when administered pre-vaccination, compared to mice vaccinated alone before exposure. In this randomized, controlled clinical study, the researchers wanted to evaluate the effect of AHCC in improving the immune responses of healthy adults to the 2009-2010 influenza vaccine. Blood samples were drawn before and three weeks after vaccination and subjects were supplemented with either controls or AHCC (3 g per day).
The results show an increase in natural killer (NK) T cells and CD8(+) cells in the AHCC supplementation group. AHCC supplementation was also shown to significantly improve antibody titers to influenza B, compared to the control group.

Study 6:
This comprehensive study started at the in-vitro stage and continued to clinical evidence of the effect of AHCC intake on the host’s immune system to clear high-risk human papillomavirus (HR-HPV). The cell culture aspect of this study used cervical cancer cells – CaSki (HPV16+), HeLa(HPV18+), SiHa(HPV16/18+), and C-33A(HPV−), which were treated with AHCC – 0.42 mg/mL daily for seven days, then observed daily for seven days, with daily sample collection. In the mouse models, mice were divided into three groups and dosed with AHCC (50 mg/kg/day), the vehicle or no supplementation for 90 days, followed by 30 days of observation. This was followed by two human pilot studies in women with confirmed persistent HR-HPV+ infections. The first study evaluated AHCC 3 g from five weeks up to six months and 2nd study evaluated AHCC 1g < eight months. HR-HPV DNA status and the immune panel were monitored at each visit.

From in-vitro to human studies, the researchers showed HR-HPV clearance. In the human studies, this effect was observed in 66.67% of the patients supplementing with AHCC after three to six months of supplementation. A confirmatory phase II randomized, double-blinded, placebo-controlled study is ongoing.

Anticancer – Chemopreventative/Chemotherapeutic:
Study 1:
In this randomized, placebo-controlled, double-blinded study, 32 patients with epithelial ovarian cancer (EOC) receiving platinum-based chemotherapy, were allocated to one of two groups – placebo or 500 mg AHCC three times daily, throughout six cycles of chemotherapy. Patients were not allowed to receive other drugs or nutritional supplements during the trial. The primary outcome was a change of CD4+ and CD8+ T cell lymphocytes in peripheral blood samples from baseline to completion of chemotherapy. Secondary outcomes were the rate of bone marrow suppression, adverse events, and quality of life (QOL) as assessed by the Thai version of the Functional Assessment of Cancer Therapy-General (FACT-G).
The results show a statistically higher level of CD8(+) cells in the AHCC group, compared to the placebo, suggesting that AHCC might act as an immuno-enhancer to decrease adverse events of chemotherapy.

Study 2:
This study explored the effects of AHCC supplementation on adverse events in breast cancer patients treated with anthracyclines and taxanes from 2004 to 2011. 41 patients were separated into two groups: group 1 – patients who took AHCC along with chemotherapy; group 2 – patients who didn’t take any AHCC along with chemotherapy. The analysis showed that, compared to the control group, the AHCC group experienced fewer neutrophil-related events, significantly lower use of granulocyte colony-stimulating factor, and fewer side effects associated with total cholesterols and triglycerides, as well as chemotherapy-induced liver damage. The authors conclude that AHCC has the potential to improve neutropenia induced by chemotherapy in the treatment of breast cancer.

Study 3:
Another study in patients with advanced cancers was carried out to determine the safety and effectiveness of AHCC on chemotherapy-induced adverse effects and quality of life. Twenty-four patients with cancer received their first cycle of chemotherapy without AHCC and then received their second cycle with AHCC. During chemotherapy cycles, patients were monitored weekly for adverse events and quality of life by a blood test, DNA levels of herpes virus type 6 (HHV-6), and questionnaires. Results show that AHCC significantly reduced the levels of HHV-6 in saliva and improved quality of life scores on the questionnaires.

Study 4:
This study was conducted to determine the effect of AHCC on chemotherapy-related adverse events in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). Patients receiving gemcitabine as the first-line chemotherapy were assigned to one of two groups – an AHCC group (6g per day) and a control group for two months.
The results show that AHCC supplementation was associated with suppression of C-reactive protein increase and albumin decreased, compared to the control group, during chemotherapy administration. Additionally, patients in the AHCC group experienced less frequency of taste disorder caused by gemcitabine. The researchers conclude that AHCC is effective in improving quality of life and reducing adverse events associated with gemcitabine administration in patients with PDAC.

Study 5:
In this prospective cohort study, 269 patients with histologically confirmed hepatocellular carcinoma (HCC) were assessed for the beneficial effects of AHCC supplementation after liver tumor resection. Patients were examined for “time to treatment failure (disease recurrence/death) and ten parameters related to liver function following tumor resection”. Patients were randomized to receive AHCC daily or no supplementation.
The results showed that the group receiving AHCC has a significantly longer no recurrence period and an increased overall survival rate than the control group, suggesting that AHCC can play an important role in improving the prognosis of HCC patients, after liver tumor resection.